Report      Database

    Asia Cervical Cancer Test Market Growth Opportunity in VIA Test Market & Pap Smear Test Market
    24 Apr, 2017


    Cervical cancer is one of the most common cancer among the women in Asian region. More than 280 Thousand new cases diagnosed each year and due to non preventive action taken timely, every year cervical cancer related death has cross over 140 Thousand. Testing is the best way to prevent and cure the disease. In the Asian region most common preventive cervical cancer methods are:  Pap smear test, HPV DNA Test and VIA test. Our Report title Cervical Cancer Test Market & Patients (Pap Smear HPV DNA VIA) Asia (Japan, Korea, Singapore, Malaysia, India, China, Thailand, Indonesia)” provides details of the following points:

    • Asia Cervical Cancer Testing Population (Pap, HPV DNA, VIA)
    • Asia Cervical Cancer Testing Market ((Pap, HPV DNA, VIA)
    • Asia Cervical Cancer Mortality Population
    • Asian Countries (Japan, Korea, Singapore, Malaysia, India, China, Thailand, Indonesia)


    Japan is playing the leading role in Asia Cervical Cancer Pap Smear Test Market

    Pap smear is commonly known Pap test, is an exam a doctor uses to test for cervical cancer in women. A Pap smear is a microscopic examination of cells taken from the uterine cervix. A Pap smear can detect human papillomavirus (HPV), which is main cause of cervical cancer. Early treatment of precancerous changes detected on the Pap smear can stop cervical cancer before it fully develops. The primary healthcare in Japan performs well in managing people suffering from chronic diseases and preventing unnecessary hospitalizations.  In 2013, cervical cancer screening rate in Japan has grown to 42.1 percent of the women population age group between 20-69 years, form 23.7 percent in 2003. Japan has a major market share in global cervical cancer test market.


    HPV DNA Test market is the 2nd Largest Market in Asia

    Human papillomavirus (HPV) infection is now a well-established cause of cervical cancer. HPV types 16 and 18 are responsible for about 70% of all cervical cancer cases. HPV vaccines that prevent HPV 16 and 18 infections are now available and have the potential to reduce the incidence of cervical. It is anticipated that Asia has 1.63 Billion women population aged 15 years and older who are at risk of developing cervical cancer. As a result, HPV DNA test market has good potential to grow in the region.


    VIA Test Market is in novice stage and mainly used in Middle and Low Income Countries

    VIA test market is in novice stage and mainly used in middle and low income countries such as India, China, Thailand, Indonesia etc. VIA test is popular in Asian region due to its low testing cost and its immediate result.  The main advantage of VIA test is that it can perform on primary healthcare center.  It does not require complicated equipment and can be done by trained health workers.


    About Us

    Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.


    Contact Us

    Renub Research

    Phone: +1-678-302-0700



    Follow us on LinkedIn:

    Related Products